Northland Biotech Showcases Innovative Gene Therapy Sedoming Injection (NL003) at the 24th Union Medical Vascular Conference (VEC)

(Source:Northland）

From May 14 to 16, 2026, the Xiehe Vascular Medicine Conference and the 24th China Vascular and Endovascular Conference (VEC) will be held at the Beijing Hotel. Hosted by the Chinese Society of Microcirculation, the conference has been running for 23 years since its establishment in 2003 and is one of the most influential academic meetings in the field of vascular surgery in China. Northland was invited to participate in this year’s conference and conducted a series of academic exchange activities around the innovative product Cedominogene Injekta (NL003), marking the first full debut of this innovative drug on a top vascular surgery academic platform in China.

Thematic Academic Report: Providing New Ideas for Clinical Treatment

Professor Di Xiao from the Vascular Surgery Department of Peking Union Medical College Hospital was invited to give a speech titled "Clinical Value of HGF Gene Therapy in "No-Option" CLTI Patients: An Academic Report. The report, starting with the overall progress of gene therapy drugs in the field of angiogenesis, elaborates in depth on the mechanism of HGF promoting angiogenesis.System,And combine the completedClinical data from the HOPE CLTI-2 study demonstrates its therapeutic value in real-world patients, providing...Bedside treatment offers new insights.

CLTI is the end-stage manifestation of peripheral artery disease progression, with persistent resting pain, limb ulcers, or gangrene as the main clinical features. Current interventional and surgical treatments fail to provide effective revascularization for a significant proportion of patients, resulting in high rates of amputation and mortality, indicating a substantial unmet clinical treatment need. As an innovative gene therapy drug independently developed in China that has entered Phase III clinical trials specifically for CLTI indications, Cedominogene Injection offers a novel pharmacological treatment approach for this challenging patient population through its mechanism of promoting therapeutic angiogenesis and reconstructing collateral circulation in ischemic limbs.

Professor Di Xiao's report focuses on the treatment dilemmas and clinical pain points faced by this patient group, using evidence-based data to demonstrate.HGF Gene Therapy Promotes Angiogenesis and Improves Limb Blood Supply, Triggering High Attention and In-Depth Academic Discussion Among Attendees.

With the help of this sessionVEC Conference: A Rare Gathering of China's Top Vascular Surgery Experts, with the Concurrent "Expert Consensus on the Clinical Application of Cedomin Injection" Seminar. Vascular surgery experts from several large medical centers in China, with extensive experience in CLTI diagnosis and treatment, thoroughly discussed core clinical issues such as patient selection, dosing regimens, safety management, and efficacy evaluation for Cedomin injection.Discussion,And discussed the consensus text based on existing evidence, jointly exploring the future of Cedomigine Injection inClinical Positioning in the Standardized Diagnosis and Treatment of CLTI.

Expert consensus, an academic document formed based on published clinical research data and the collective clinical judgment of attending experts, aims to provide standardized medication reference for clinicians after product approval and market launch, facilitating the scientific and rational application of innovative therapies in clinical practice.

Cedomidine InjectionIn July 2024, it was officially accepted by the National Medical Products Administration (NMPA) (Acceptance No.: CXSS2400066). All technical reviews have been completed, and it is currently in the final stage of marketing approval.Paragraph.This seminar promoted the development of expert consensus,The evidence-based support system for the product will be further improved, which will help guide the rational use of the drug in clinical practice after approval. As the marketing authorization process continues to advance, Northland will actively prepare for commercial deployment, striving to make the product accessible to more people."Non-option" CLTI patients receive effective treatment, pushing vascular surgery in China to a new level in this difficult-to-treat field.

Disclaimer for Forward-Looking Statements

The products involved in this article are within the scope of national pharmaceuticalsSupervision and Administration BureauApprovalStage, not yet approved for marketing, itsApprovalThe progress and market launch timeline are reasonable expectations based on current information and do not constitute any form of commitment or guarantee. Actual...ApprovalConclusion and market launch time depend on the independent review of regulatory authorities and may differ from the current forecast.There are differences in the term. This article is for academic exchange and R&D progress reference only, and does not constitute any drug promotion, investment advice, or medical advice.